Marinus Pharmaceuticals Q4 2022 Earnings Report

Marinus Pharmaceuticals EPS Results

• Actual EPS: -$0.76
• Consensus EPS: -$0.91
• Beat/Miss: Beat by +$0.15
• One Year Ago EPS: N/A

Marinus Pharmaceuticals Revenue Results

• Actual Revenue: $7.16 million
• Expected Revenue: $13.32 million
• Beat/Miss: Missed by -$6.16 million
• YoY Revenue Growth: N/A

Marinus Pharmaceuticals Announcement Details

• Quarter: Q4 2022
• Date: 3/7/2023
• Time: N/A

Marinus Pharmaceuticals (NASDAQ:MRNS), a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.